Literature DB >> 26140251

Cross-talk between tumors can affect responses to therapy.

Christel Devaud1, Liza B John1, Jennifer A Westwood1, Carmen Sm Yong1, Paul A Beavis1, Reto A Schwendener2, Phillip K Darcy3, Michael H Kershaw3.   

Abstract

Advanced stages of cancer often involve multiple tumors in different locations in the body. These tumors are associated with a microenvironment that can influence tumor responses to immunotherapy. Whether tumors and their disparate microenvironment can interact together at distance in a multiple tumor setting, through a form of cross-talk, and affect their responses to immunotherapy has never been described. Our study investigated the cross-talk between two tumors with disparate microenvironments in a mouse model. We demonstrated that immunosuppressive visceral tumors could influence distant subcutaneous (SC) tumors to render them resistant to immunotherapy. We observed distinct modifications in the SC tumor microenvironment following cross-talk with kidney tumors that exhibit a type-2 macrophage-related immunosuppressive microenvironment. Indeed, when a concomitant kidney tumor was present in the mouse, the SC tumors were highly infiltrated with M2 macrophages and had a reduced T cell and NK cell effector immune profile. Finally, blocking the M2-associated chemokine CCL2 or depleting macrophages, significantly improved the effect of immunotherapy on growth of SC tumors in the presence of concomitant kidney tumors. This work emphasizes the potential negative influence that a tumor, with a strong immunosuppressive microenvironment, can exert on distant tumors that would normally be treatment-responsive. This report may lead to a new vision of the prioritization in the treatment of advanced metastatic cancer.

Entities:  

Keywords:  C-C motif ligand-2; CD; CCL2; CD137; CD40; DR5; T cell receptor.; clodronate; cluster of differentiation; IFNγ; immunosuppression; immunotherapy; interferon gamma; IH; interleukin; M2; intrahepatic; IK; intrakidney; IL; natural killer; SC; subcutaneous; TCR; tumor immunology; tumor microenvironment; type 2 macrophages; NK; type-2 macrophages

Year:  2015        PMID: 26140251      PMCID: PMC4485781          DOI: 10.4161/2162402X.2014.975572

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  50 in total

Review 1.  Cellular constituents of immune escape within the tumor microenvironment.

Authors:  Sid P Kerkar; Nicholas P Restifo
Journal:  Cancer Res       Date:  2012-06-21       Impact factor: 12.701

Review 2.  Paradoxical roles of the immune system during cancer development.

Authors:  Karin E de Visser; Alexandra Eichten; Lisa M Coussens
Journal:  Nat Rev Cancer       Date:  2006-01       Impact factor: 60.716

3.  Effector/memory but not naive regulatory T cells are responsible for the loss of concomitant tumor immunity.

Authors:  Yung-Chang Lin; Li-Yuan Chang; Ching-Tai Huang; Hui-Min Peng; Avijit Dutta; Tse-Ching Chen; Chau-Ting Yeh; Chun-Yen Lin
Journal:  J Immunol       Date:  2009-05-15       Impact factor: 5.422

4.  Fast gapped-read alignment with Bowtie 2.

Authors:  Ben Langmead; Steven L Salzberg
Journal:  Nat Methods       Date:  2012-03-04       Impact factor: 28.547

5.  Control of TH2 polarization by the chemokine monocyte chemoattractant protein-1.

Authors:  L Gu; S Tseng; R M Horner; C Tam; M Loda; B J Rollins
Journal:  Nature       Date:  2000-03-23       Impact factor: 49.962

6.  Patients with melanoma metastases at cutaneous and subcutaneous sites are highly susceptible to interleukin-2-based therapy.

Authors:  E Chang; S A Rosenberg
Journal:  J Immunother       Date:  2001 Jan-Feb       Impact factor: 4.456

7.  Tissues in different anatomical sites can sculpt and vary the tumor microenvironment to affect responses to therapy.

Authors:  Christel Devaud; Jennifer A Westwood; Liza B John; Jacqueline K Flynn; Sophie Paquet-Fifield; Connie P M Duong; Carmen S M Yong; Hollie J Pegram; Steven A Stacker; Marc G Achen; Trina J Stewart; Linda A Snyder; Michele W L Teng; Mark J Smyth; Phillip K Darcy; Michael H Kershaw
Journal:  Mol Ther       Date:  2013-09-19       Impact factor: 11.454

8.  Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.

Authors:  Daniel Y C Heng; Wanling Xie; Meredith M Regan; Mark A Warren; Ali Reza Golshayan; Chakshu Sahi; Bernhard J Eigl; J Dean Ruether; Tina Cheng; Scott North; Peter Venner; Jennifer J Knox; Kim N Chi; Christian Kollmannsberger; David F McDermott; William K Oh; Michael B Atkins; Ronald M Bukowski; Brian I Rini; Toni K Choueiri
Journal:  J Clin Oncol       Date:  2009-10-13       Impact factor: 44.544

Review 9.  The tumor microenvironment and its role in promoting tumor growth.

Authors:  T L Whiteside
Journal:  Oncogene       Date:  2008-10-06       Impact factor: 9.867

10.  Enhanced antitumor immunity in mice deficient in CD69.

Authors:  Enric Esplugues; David Sancho; Javier Vega-Ramos; Carlos Martínez; Uta Syrbe; Alf Hamann; Pablo Engel; Francisco Sánchez-Madrid; Pilar Lauzurica
Journal:  J Exp Med       Date:  2003-05-05       Impact factor: 14.307

View more
  5 in total

1.  A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies.

Authors:  Katherine A Murphy; Britnie R James; Andrew Wilber; Thomas S Griffith
Journal:  J Vis Exp       Date:  2017-04-12       Impact factor: 1.355

Review 2.  Tissue-Dependent Tumor Microenvironments and Their Impact on Immunotherapy Responses.

Authors:  Amanda J Oliver; Peter K H Lau; Ashleigh S Unsworth; Sherene Loi; Phillip K Darcy; Michael H Kershaw; Clare Y Slaney
Journal:  Front Immunol       Date:  2018-01-31       Impact factor: 7.561

3.  Apigenin inhibits TNFα/IL-1α-induced CCL2 release through IKBK-epsilon signaling in MDA-MB-231 human breast cancer cells.

Authors:  David Bauer; Natalie Redmon; Elizabeth Mazzio; Karam F Soliman
Journal:  PLoS One       Date:  2017-04-25       Impact factor: 3.240

Review 4.  The Liver-Immunity Nexus and Cancer Immunotherapy.

Authors:  James C Lee; Michael D Green; Laura A Huppert; Christine Chow; Robert H Pierce; Adil I Daud
Journal:  Clin Cancer Res       Date:  2021-07-20       Impact factor: 12.531

5.  Primary and metastatic breast tumors cross-talk to influence immunotherapy responses.

Authors:  Amanda J Oliver; Simon P Keam; Bianca von Scheidt; Damien J Zanker; Aaron J Harrison; Daniela Gm Tantalo; Phillip K Darcy; Michael H Kershaw; Clare Y Slaney
Journal:  Oncoimmunology       Date:  2020-08-30       Impact factor: 8.110

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.